Coccidioidomycosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 46 Published: March 31, 2022 Report Code: GMDGDHC22094IDB

Coccidioidomycosis, also called Valley fever, is an infection caused by the fungus Coccidioides. Symptoms include fever, cough, chest pain, chills, headache, fatigue, and joint aches. Risk factors include the weakened immune system, age, pregnancy, race, and environmental exposure. Treatment includes antifungal medications.

The Coccidioidomycosis drugs in development market research report provide comprehensive information on the therapeutics under development for Coccidioidomycosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects.

Key Targets in the Coccidioidomycosis Pipeline Products Market

The key targets in the Coccidioidomycosis pipeline products market are Lanosterol 14 Alpha Demethylase, 1,3 Beta Glucan Synthase, Chitin Synthase, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, Ergosterol, GPI Anchored Wall Transfer Protein 1, and Smoothened Homolog.

Coccidioidomycosis Pipeline Products Analysis Market by Targets

Coccidioidomycosis Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Coccidioidomycosis Pipeline Products Market

The key mechanisms of action in the Coccidioidomycosis pipeline products market are Lanosterol 14 Alpha Demethylase Inhibitor, 1,3 Beta Glucan Synthase Inhibitor, Chitin Synthase Inhibitor, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, Ergosterol Inhibitor, GPI Anchored Wall Transfer Protein 1 Inhibitor, and Smoothened Homolog Antagonist.

Coccidioidomycosis Pipeline Products Market Analysis by Mechanism of Actions

Coccidioidomycosis Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Coccidioidomycosis Pipeline Products Market

The key routes of administration in the Coccidioidomycosis pipeline products market are oral, intravenous, and topical.

Coccidioidomycosis Pipeline Products Market Analysis by Routes of Administration

Coccidioidomycosis Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Coccidioidomycosis Pipeline Products Market

The key molecule types in the Coccidioidomycosis pipeline products market are small molecule and vaccine.

Coccidioidomycosis Pipeline Products Market Analysis by Molecule Type

Coccidioidomycosis Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Coccidioidomycosis Pipeline Products Market

Some of the major companies in the Coccidioidomycosis pipeline products market are Acea Biotech Inc, F2G Ltd, Mayne Pharma Group Ltd, Mycovia Pharmaceuticals Inc, Pfizer Inc, Scynexis Inc, and Valley Fever Solutions Inc.

Coccidioidomycosis Pipeline Products Market Analysis by Companies

Coccidioidomycosis Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Lanosterol 14 Alpha Demethylase, 1,3 Beta Glucan Synthase, Chitin Synthase, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, Ergosterol, GPI Anchored Wall Transfer Protein 1, and Smoothened Homolog
Key mechanism of action Lanosterol 14 Alpha Demethylase Inhibitor, 1,3 Beta Glucan Synthase Inhibitor, Chitin Synthase Inhibitor, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, Ergosterol Inhibitor, GPI Anchored Wall Transfer Protein 1 Inhibitor, and Smoothened Homolog Antagonist
Key routes of administration Oral, Intravenous, and Topical
Key molecule type Small Molecule and Vaccine
Major companies Acea Biotech Inc, F2G Ltd, Mayne Pharma Group Ltd, Mycovia Pharmaceuticals Inc, Pfizer Inc, Scynexis Inc, and Valley Fever Solutions Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Coccidioidomycosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Coccidioidomycosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Coccidioidomycosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Coccidioidomycosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Coccidioidomycosis (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Coccidioidomycosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Coccidioidomycosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • Acea Biotech Inc

    F2G Ltd

    Mayne Pharma Group Ltd

    Mycovia Pharmaceuticals Inc

    Pfizer Inc

    Scynexis Inc

    Valley Fever Solutions Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Coccidioidomycosis – Overview

Coccidioidomycosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Coccidioidomycosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Coccidioidomycosis – Companies Involved in Therapeutics Development

Acea Biotech Inc

F2G Ltd

Mayne Pharma Group Ltd

Mycovia Pharmaceuticals Inc

Pfizer Inc

Scynexis Inc

Valley Fever Solutions Inc

Coccidioidomycosis – Drug Profiles

Amphotericin B sodium – Drug Profile

Product Description

Mechanism Of Action

coccidioidomycosis vaccine – Drug Profile

Product Description

Mechanism Of Action

fosmanogepix – Drug Profile

Product Description

Mechanism Of Action

History of Events

ibrexafungerp citrate – Drug Profile

Product Description

Mechanism Of Action

History of Events

itraconazole – Drug Profile

Product Description

Mechanism Of Action

History of Events

nikkomycin Z – Drug Profile

Product Description

Mechanism Of Action

History of Events

olorofim – Drug Profile

Product Description

Mechanism Of Action

History of Events

VT-1598 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Coccidioidomycosis – Dormant Projects

Coccidioidomycosis – Product Development Milestones

Featured News & Press Releases

Oct 22, 2020: F2G receives second US FDA Breakthrough Therapy Designation for Olorofim

Jun 10, 2020: F2G’s Olorofim receives both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections

Oct 24, 2019: SCYNEXIS expands FURI protocol to a broader range of refractory serious fungal infections, building on Ibrexafungerp’s positive data and favorable toxicology profile observed to date

Sep 09, 2019: FDA grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for seven different indications

Jun 07, 2018: Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

Jul 13, 2017: FDA Grants Fast Track Designation to VT-1598 for Treatment of Valley Fever

May 17, 2017: Viamet To Present Data on VT-1598 at The American Society for Microbiology’s ASM Microbe 2017 Conference

Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

Sep 15, 2016: FDA Grants QIDP Designation to VT-1598 for Treatment of Valley Fever

Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections

May 25, 2016: Viamet Receives Orphan Drug Designation from the FDA for VT-1598 for the Treatment of Coccidioidomycosis

May 20, 2015: Viamet Announces NIH Grant for Compounds Directed at Valley Fever

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Coccidioidomycosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Coccidioidomycosis – Pipeline by Acea Biotech Inc, 2022

Coccidioidomycosis – Pipeline by F2G Ltd, 2022

Coccidioidomycosis – Pipeline by Mayne Pharma Group Ltd, 2022

Coccidioidomycosis – Pipeline by Mycovia Pharmaceuticals Inc, 2022

Coccidioidomycosis – Pipeline by Pfizer Inc, 2022

Coccidioidomycosis – Pipeline by Scynexis Inc, 2022

Coccidioidomycosis – Pipeline by Valley Fever Solutions Inc, 2022

Coccidioidomycosis – Dormant Projects, 2022

List of Figures

List of Figures

Number of Products under Development for Coccidioidomycosis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.